Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
TRML Tourmaline Bio Inc
- Stocks
- Healthcare
- NASDAQ: TRML
Price (delayed)
$15.18
Market cap
$389.95M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$3.22
Enterprise value
$354.59M
talaris therapeutics is a late-clinical stage biotechnology company based in boston, ma and louisville, ky. talaris is developing transformative cell therapies with the potential to eliminate the burden of chronic
Highlights
The company's debt fell by 48% YoY and by 20% QoQ
The quick ratio has contracted by 46% YoY but it has grown by 13% from the previous quarter
TRML's EPS has dropped by 119% year-on-year and by 11% since the previous quarter
Tourmaline Bio's net income has shrunk by 73% YoY and by 13% QoQ
Key stats
What are the main financial stats of TRML
Market
Valuations
Earnings
Shares outstanding
25.69M
Market cap
$389.95M
Enterprise value
$354.59M
Price to earnings (P/E)
N/A
Price to book (P/B)
1.39
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$98.45M
Net income
-$82.87M
EBIT
-$82.87M
EBITDA
-$82.67M
Free cash flow
-$84.04M
Per share
Balance sheet
Liquidity
EPS
-$3.22
EPS diluted
-$3.22
Free cash flow per share
-$3.27
Book value per share
$10.9
Revenue per share
$0
TBVPS
$11.19
Total assets
$287.5M
Total liabilities
$7.64M
Debt
$196,000
Equity
$279.86M
Working capital
$250.52M
Debt to equity
0
Current ratio
33.87
Quick ratio
32.74
Net debt/EBITDA
0.43
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-26.1%
Return on equity
-26.7%
Return on invested capital
-31%
Return on capital employed
-29.6%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
TRML stock price
How has the Tourmaline Bio stock price performed over time
Intraday
-3.56%
1 week
-6.87%
1 month
21.68%
1 year
-3.74%
YTD
-25.15%
QTD
-0.2%
Financial performance
How have Tourmaline Bio's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$98.45M
Net income
-$82.87M
Gross margin
N/A
Net margin
N/A
Tourmaline Bio's operating income has plunged by 78% YoY and by 10% from the previous quarter
Tourmaline Bio's net income has shrunk by 73% YoY and by 13% QoQ
Price vs fundamentals
How does TRML's price correlate with its fundamentals
Growth
What is Tourmaline Bio's growth rate over time
Valuation
What is Tourmaline Bio stock price valuation
P/E
N/A
P/B
1.39
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
TRML's EPS has dropped by 119% year-on-year and by 11% since the previous quarter
TRML's equity is down by 21% year-on-year and by 7% since the previous quarter
The price to book (P/B) is 4% lower than the last 4 quarters average of 1.5
Efficiency
How efficient is Tourmaline Bio business performance
The company's return on assets fell by 20% QoQ and by 20% YoY
Tourmaline Bio's ROE has decreased by 20% from the previous quarter and by 19% YoY
TRML's return on invested capital is up by 15% year-on-year but it is down by 14% since the previous quarter
Dividends
What is TRML's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for TRML.
Financial health
How did Tourmaline Bio financials performed over time
TRML's total liabilities has soared by 52% YoY but it is down by 15% from the previous quarter
The quick ratio has contracted by 46% YoY but it has grown by 13% from the previous quarter
The company's debt is 100% lower than its equity
The company's debt fell by 48% YoY and by 20% QoQ
TRML's equity is down by 21% year-on-year and by 7% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.